Keros Therapeutics Presents Results from Preclinical Study of KER-012 in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference
May 14, 2021 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery,...
Keros Therapeutics to Present at the Virtual 26th Annual Congress of the European Hematology Association
May 12, 2021 16:01 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results
May 06, 2021 16:01 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery,...
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results
March 25, 2021 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery,...
Keros Therapeutics Presents Results from Preclinical Studies of KER-050 and ALK2 Inhibitors at the European School of Haematology (ESH) 2nd Translational Research E-Conference
March 05, 2021 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery,...
Keros Therapeutics to Present at the H.C. Wainwright Global Life Sciences 2021 Virtual Conference
March 02, 2021 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Keros Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
February 17, 2021 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Keros Therapeutics Announces Addition to NASDAQ Biotechnology Index
December 21, 2020 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Keros Therapeutics Appoints Mary Ann Gray, Ph.D., to its Board of Directors
December 17, 2020 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery,...
Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its ALK2 Inhibitor Program, Including KER-047 Phase 1 Data, and KER-050 Preclinical Data, at the Virtual 62nd American Society of Hematology Annual Meeting and Exposition
December 07, 2020 08:00 ET
|
Keros Therapeutics, Inc.
Presentation highlights data from Keros’ Phase 1 clinical trial of KER-047, which demonstrated robust and sustained dose-related increases in serum iron and transferrin saturation that were associated...